On 10th July, a new collection center in Augsburg (Bavaria), managed by KEDPlasma GmbH on behalf of Kedrion Biopharma, has been inaugurated with an official opening ceremony. Kedrion now owns 17 collection centers worldwide, four of which are located in Germany: Ingolstadt, Fürth, Bayreuth and Augsburg.
The new collection center, staffed by team of 11 under the supervision of Center Manager Brigitte Hübner, is situated in the heart of the city, on the second and third floors of a building facing City Hall Square (Rathausplatz, Philippine-Welser-Straße 8). The center is able to welcome up to 40 donors at the same time. Their altruistic donations are essential to the production of life-saving therapies.
“Thanks to KEDPlasma´s new center, Augsburg´s citizens can donate plasma and contribute to help providing life-saving plasma-derived therapies to the growing number of patients that Kedrion Biopharma´s German sales team serves”, stated Stephan Walsemann, Managing Director of KEDPlasma Germany.
The opening ceremony of the new KEDPlasma center in Augsburg featured a tour of the facility and a plasma donation demonstration. Kedrion’s Global Communication Director Marialina Marcucci, Dr. Stephan Walsemann, Dr. Brigitte Hübner and a city council of Augsburg, Rudolf Holzapfel, amongst others, attended the event. "I was impressed – commented Stephan Walsemann – by the very warm welcome of the representatives of the town of Augsburg during the opening ceremony and the offered hands to support our business”.
KEDPlasma works with donors in America and in Europe to collect plasma in state-of-the-art collections centers located in Germany, Hungary and the United States. Plasma is then industrially processed in Kedrion Biopharma’s manufacturing plants to produce plasma-derived therapies for the treatment of serious diseases and conditions such as hemophilia and immunodeficiencies.
KEDPlasma GmbH’s headquarters are in Gräfelfing, near Munich, in Bavaria (Germany). It manages four collection centers in Ingolstadt, Fürth, Bayreuth and Augsburg, employing over 100 staff.
Kedrion Biopharma has a commercial presence in the German market, and works in close partnership with the KEDPlasma team to ensure patient access to the life-saving therapies it distributes in the country. Immunoglobulins for the treatment of immunodeficiencies and hepatitis B, and albumin for use in critical care settings, are amongst the products Kedrion makes available in Germany.
Kedrion Biopharma’s mission is to act as a bridge, a vital connection between donors and patients in need of care, collecting plasma to manufacture plasma-derived medicinal specialties.
In our plasma collection centers, a procedure called plasmapheresis is carried out whereby whole blood plasma is separated, and the corpusculate part (red cells and platelets) is reinfused into the donor. The procedure usually requires approximately 45 minutes and, as plasma is rapidly replenished, donation frequency is higher compared to whole blood donations.
After collection, plasma is quickly frozen so it can be safely stored. Plasma is used as raw material to obtain plasma-derived products. To do this, plasma is separated into its various constituents in a process called fractionation. The isolated proteins are the constituents of plasma derivative products including clotting factors, albumin and immunoglobulins. Plasma-derived therapies are used by millions of people over the world for the treatment of several diseases – some severe – like hemophilia and immune deficiency disorders.
Kedrion upholds, documents and implements its processes and activities in accordance with the highest international standards of quality, including QSEAL (Quality Standards of Excellence, Assurance and Leadership) and IQPP (International Quality Plasma Program) voluntary certification, both awarded by the Plasma Protein Therapeutics Association (PPTA).
More information on plasma donation, plasma-derived therapies and diseases is available from our website www.kedplasma.de.